{"id":"W2495862253","doi":"10.1182/blood.v126.23.4777.4777","title":"First in Human Single-Ascending Dose Study: Safety, Biomarker, Pharmacokinetics and Exposure-Response Relationships of ALXN1210, a Humanized Monoclonal Antibody to C5, with Marked Half-Life Extension and Potential for Significantly Longer Dosing Intervals","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"inVentiv Health Clinical","funders":"","keywords":"Medicine; Pharmacokinetics; Cmax; Eculizumab; Pharmacodynamics; Pharmacology; Tolerability; Immunogenicity; Internal medicine; Paroxysmal nocturnal hemoglobinuria; Gastroenterology; Placebo; Adverse effect; Atypical hemolytic uremic syndrome; Immunology; Complement system; Antibody; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001489522,0.0002472881,0.0004703118,0.0003584084,0.000261208,0.00004188272,0.0001450556,0.00009328332,0.00004021371],"category_scores_gemma":[0.0003784912,0.0002272704,0.00004889922,0.0001809246,0.0001362127,0.0001034411,0.0001951958,0.0001232662,0.00000221654],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003582933,"about_ca_system_score_gemma":0.0000546945,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000766986,"about_ca_topic_score_gemma":0.0001385005,"domain_scores_codex":[0.9976074,0.0008443677,0.0006679902,0.0004772636,0.0000959856,0.0003069961],"domain_scores_gemma":[0.9986839,0.000552175,0.0002474897,0.0002559764,0.0001629837,0.00009749406],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.01495119,0.001911555,0.1441665,0.0001018985,0.0004044464,0.00003407738,0.002380379,0.00003144225,0.8356125,0.0000223756,0.000190936,0.0001926695],"study_design_scores_gemma":[0.04361359,0.003638611,0.9303738,0.0006430299,0.0008158808,0.0001129015,0.00473305,0.0001143337,0.01510376,0.00004822471,0.0002912715,0.0005114881],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995845,0.001190743,0.0007203156,0.0001605275,0.0001266989,0.001827062,0.0000792358,0.00003882894,0.00001161777],"genre_scores_gemma":[0.9990321,0.000006214734,0.0006947679,0.00002197817,0.00002169058,0.00006153832,0.00008127347,0.00003294295,0.00004749049],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8205088,"threshold_uncertainty_score":0.9267819,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0725644227953989,"score_gpt":0.3215063060005928,"score_spread":0.2489418832051939,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}